logo

For the Inventor, By the Inventor

Ardsley, NY, United States of America

Acorda Therapeutics, Inc.


USPTO Granted Patents = 90

% Expired Patents = 55.6



Trademarks = 15

Forward Citations = 348

Loading Chart...
Loading Chart...

59 inventors (with patents filed for the assignee):

goldMedal Anthony O Caggiano (36 out of 36 patents)

silverMedal Jennifer Iaci (23 out of 23 patents)

bronzeMedal Andrea M Vecchione (16 out of 16 patents)

4.  Mark Andrew Marchionni (16 out of 24 patents)

5.  Keith R Bley (15 out of 25 patents)

6.  Elliott A Gruskin (14 out of 41 patents)

7.  Naweed Muhammad (14 out of 24 patents)

8.  Gargi Roy (8 out of 8 patents)

9.  Andrew David Goodearl (8 out of 20 patents)

10.  Luisa Minghetti (8 out of 19 patents)

11.  Paul Stroobant (8 out of 20 patents)

12.  Michael Derek Waterfield (8 out of 31 patents)

13.  Ian D Hiles (8 out of 24 patents)

14.  Andrew R Blight (6 out of 6 patents)

15.  Ron Cohen (6 out of 6 patents)


Core Competencies:
Sustained Release
4-Aminopyridine
Neuregulin
Cardiac Damage
CNS Injury
Chondroitinase
Neuronal Outgrowth
Prodrugs
Dopaminergic Neurons
Glial Growth Factor
Inflammatory Cells
Muscle Diseases

90 patents:

1. 12029820 - Sustained release compositions of 4-aminopyridine (2024-07-09),
2. 11235031 - Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure (2022-02-01),
3. 11141467 - Methods of reducing extravasation of inflammatory cells (2021-10-12),
4. 11136342 - Carbonate prodrugs and methods of using the same (2021-10-05),
5. 11071770 - Methods for detecting cardiac damage (2021-07-27),
6. 11021498 - Water-soluble acetaminophen analogs (2021-06-01),
7. 10717775 - Methods for cardiomyocyte survival, proliferation or differentiation by NRG-2 (2020-07-21),
8. 10675331 - Method for achieving desired glial growth factor 2 plasma levels (2020-06-09),
9. 10668131 - Compositions and methods for treatment during non-acute periods following CNS neurological injury (2020-06-02),
10. 10442826 - Water-soluble acetaminophen analogs (2019-10-15),
11. 10377779 - Carbonate prodrugs and methods of using the same (2019-08-13),
12. 10323240 - Compositions and methods of using chondroitinase ABCI mutants (2019-06-18),
13. 10258667 - Methods for detecting cardiac damage (2019-04-16),
14. 10232016 - Methods for treating congestive heart failure (2019-03-19),
15. 10065999 - Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by NRG-2 (2018-09-04),
Company Overview
Acorda Therapeutics, Inc. is a biopharmaceutical company based in Ardsley, NY, specializing in innovative neurological treatments. The company focuses on developing therapies that address unmet medical needs in conditions affecting the central nervous system. Acorda's core technologies include sustained release formulations and compounds such as 4-Aminopyridine, which are designed to enhance neuronal function and promote recovery from CNS injuries. Their research also explores the potential of Neuregulin and Chondroitinase in supporting neuronal outgrowth and mitigating cardiac damage.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Acorda Therapeutics, Inc. USPTO Patent Assignee Logo
90 Patents

#1 in Ardsley, NY

#258 in New York

#4,147 in US

#8,524 in the World

Ardsley, NY (US)
Ardsley, NY, United States of America

Acorda Therapeutics, Inc.

Forward Citations = 348

59 inventors:

goldMedal Anthony O Caggiano (36 out of 36 patents)

silverMedal Jennifer Iaci (23 out of 23 patents)

bronzeMedal Andrea M Vecchione (16 out of 16 patents)

4.  Mark Andrew Marchionni (16 out of 24 patents)

5.  Keith R Bley (15 out of 25 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Acorda Therapeutics, Inc.. Retrieved from https://idiyas.com/company/acorda-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…